Bicycle Therapeutics PLC
NASDAQ:BCYC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.17
21.09
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
BCYC
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 7.52 USD,
Bicycle Therapeutics PLC
is
hidden
.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Bicycle Therapeutics PLC
BCYC looks undervalued. But is it really? Some stocks live permanently below intrinsic value; one glance at Historical Valuation reveals if BCYC is one of them.
Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Bicycle Therapeutics PLC.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Bicycle Therapeutics PLC
Balance Sheet Decomposition
Bicycle Therapeutics PLC
| Current Assets | 738.8m |
| Cash & Short-Term Investments | 648.3m |
| Receivables | 67.3m |
| Other Current Assets | 23.2m |
| Non-Current Assets | 25.1m |
| PP&E | 11.4m |
| Other Non-Current Assets | 13.7m |
| Current Liabilities | 69.3m |
| Accounts Payable | 12.7m |
| Accrued Liabilities | 44m |
| Other Current Liabilities | 12.7m |
| Non-Current Liabilities | 76.2m |
| Other Non-Current Liabilities | 76.2m |
Free Cash Flow Analysis
Bicycle Therapeutics PLC
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Bicycle Therapeutics PLC
|
Revenue
|
28.3m
USD
|
|
Operating Expenses
|
-314m
USD
|
|
Operating Income
|
-285.7m
USD
|
|
Other Expenses
|
35m
USD
|
|
Net Income
|
-250.7m
USD
|
BCYC Profitability Score
Profitability Due Diligence
Bicycle Therapeutics PLC's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Bicycle Therapeutics PLC's profitability score is hidden . The higher the profitability score, the more profitable the company is.
BCYC Solvency Score
Solvency Due Diligence
Bicycle Therapeutics PLC's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Bicycle Therapeutics PLC's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BCYC Price Targets Summary
Bicycle Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for
BCYC
is 22.01 USD
with a low forecast of 6.06 USD and a high forecast of 46.2 USD.
Dividends
Current shareholder yield for
BCYC is
hidden
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BCYC
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 7.52 USD,
Bicycle Therapeutics PLC
is
hidden
.